Bayesian Capital Management, LP Novo Cure LTD Transaction History

Bayesian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $641,413 - $1.68 Million	39,716 New	39,716 $641,000
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $632,128 - $1.33 Million	11,200 New	11,200 $673,000
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $274,510 - $436,015	4,850 New	4,850 $337,000
Q2 2021 Aug 13, 2021	SELL	$130.4 - $225.58 $377,377 - $652,828	-2,894 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$124.11 - $190.17 $53,987 - $82,723	435 Added 17.69%	2,894 $383,000
Q4 2020 Feb 12, 2021	BUY	$112.16 - $174.14 $275,801 - $428,210	2,459 New	2,459 $426,000
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $154,035 - $258,525	-2,700 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$68.3 - $93.8 $184,410 - $253,260	2,700 New	2,700 $228,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.